Colorectal Cancer (CRC) Active Not Recruiting Phase 2 Trials for Durvalumab (DB11714)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03851614	Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors	Treatment	Cediranib (DB04849) Durvalumab (DB11714) Olaparib (DB09074)
NCT02888743	Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer	Treatment	Durvalumab (DB11714) Tremelimumab (DB11771)
NCT02983578	Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer	Treatment	Danvatirsen (DB14825) Durvalumab (DB11714)
NCT03228667	QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	Treatment	Atezolizumab (DB11595) Avelumab (DB11945) Docetaxel (DB01248) Durvalumab (DB11714) Inbakicept (DB16479) Nivolumab (DB09035) Nogapendekin alfa (DB18740) PD-L1 t-haNK (DB23689) Pembrolizumab (DB09037)